- Autor
-
Pracoviště
Bellvitge Biomedical Biomedical Resea... 1 CIBERCV Instituto de Salud Carlos 3 M... 1 Cardiology Division Fondazione Toscan... 1 Cardiology Service Germans Trias i Pu... 1 Department of Haematooncology Univers... 1 Department of Medicine UAB Barcelona ... 1 Faculty of Medicine University of Ost... 1 Faculty of Medicine University of Vic... 1 Faculty of Science University of Ostr... 1 ICREC Research Program Health Science... 1 Interdisciplinary Center of Health Sc... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
Bellvitge Biomedical Biomedical Resea... 1 CIBERCV Instituto de Salud Carlos 3 M... 1 Cardiology Division Fondazione Toscan... 1 Cardiology Service Germans Trias i Pu... 1 Department of Haematooncology Univers... 1 Department of Medicine UAB Barcelona ... 1 Faculty of Medicine University of Ost... 1 Faculty of Medicine University of Vic... 1 Faculty of Science University of Ostr... 1 ICREC Research Program Health Science... 1 Interdisciplinary Center of Health Sc... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Ferrer-Curriu, Gemma
- Soler-Botija, Carolina
- Charvatova, Sandra
- Motais, Benjamin
-
Roura, Santiago
Autor Roura, Santiago ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain CIBERCV, Instituto de Salud Carlos III, Madrid, Spain Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic, Barcelona 08500, Spain
- Galvez-Monton, Carolina
- Monguió-Tortajada, Marta
- Iborra-Egea, Oriol
- Emdin, Michele
- Lupón, Josep
NLK
Directory of Open Access Journals
od 2018
Elsevier Open Access Journals
od 2018-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
PubMed
36495661
DOI
10.1016/j.biopha.2022.114061
Knihovny.cz E-zdroje
Fibrosis is present in an important proportion of myocardial disorders. Injury activates cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness, impairing cardiac function, and leading to heart failure. Clinical therapies that directly target excessive fibrosis are limited, and more effective treatments are needed. Immunotherapy based on chimeric antigen receptor (CAR) T cells is a novel technique that redirects T lymphocytes toward specific antigens to eliminate the target cells. It is currently used in haematological cancers but has demonstrated efficacy in mouse models of hypertensive cardiac fibrosis, with activated fibroblasts as the target cells. CAR T cell therapy is associated with significant toxicities, but CAR natural killer cells can overcome efficacy and safety limitations. The use of CAR immunotherapy offers a potential alternative to current therapies for fibrosis reduction and restoration of cardiac function in patients with myocardial fibrosis.
- MeSH
- chimerické antigenní receptory * MeSH
- fibróza MeSH
- imunoterapie adoptivní škodlivé účinky metody MeSH
- imunoterapie metody MeSH
- kardiomyopatie * farmakoterapie MeSH
- myši MeSH
- nádory * farmakoterapie MeSH
- T-lymfocyty MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.